X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AVB-202 is being developed with a transgene to encode full-length frataxin protein (210 amino acids) packaged into an AAV9 capsid under the control of a promoter specifically designed to drive expression in neurons and cardiac cells.
Lead Product(s): AVB-202
Therapeutic Area: Genetic Disease Product Name: AVB-202
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Solid Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 05, 2022
Details:
AVB-202 is being developed with a transgene to encode full-length frataxin protein (210 amino acids) packaged into an AAV9 capsid under the control of a promoter specifically designed to drive expression in neurons and cardiac cells.
Lead Product(s): AVB-202
Therapeutic Area: Genetic Disease Product Name: AVB-202
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Solid Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 30, 2022
Details:
The expansion of partnership will enable AavantiBio to further build out its platform focused on advancing innovative next generation AAV gene therapies focused on AAV’s capsid in areas of significant unmet medical need.
Lead Product(s): AAV-based Capsid
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: University of Florida
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 12, 2021
Details:
Aldevron will provide plasmids for AavantiBio’s future gene therapy programs, including the company’s neuromuscular and CNS pipeline programs.
Lead Product(s): Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Aldevron
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 21, 2021
Details:
Resilience will provide process development and GMP manufacturing services including cell lines and viral banks for AavantiBio’s AVV-based therapeutic FA candidate for use in both pre-clinical studies, and Phase I/II trials in the U.S. and Europe.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Resilience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 03, 2021
Details:
Catalent will provide process development and CGMP manufacturing of AavantiBio’s adeno-associated viral (AAV) vector-based therapeutic candidate for use in clinical trials in the U.S. and Europe.
Lead Product(s): AAV-based gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 27, 2021
Details:
AavantiBio will pursue a diversified gene therapy pipeline, including a lead program in Friedreich’s Ataxia (FA), a rare inherited genetic disease characterized by cardiac and central nervous system dysfunction.
Lead Product(s): Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sarepta Therapeutics
Deal Size: $107.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
